GEN Podcasts

Looking at the CAR-T Landscape As First Approval Nears


Listen Later

GEN Sounds of Science July 18, 2017Brad Loncar, CEO of Loncar Investments, discusses the outlook for chimeric antigen receptor T cell (CAR-T) cancer therapies as Novartis nears FDA approval for the first such treatment, CTL019. Some other CAR-T therapies have also shown early, yet promising, clinical data.

Hosted on Acast. See acast.com/privacy for more information.

...more
View all episodesView all episodes
Download on the App Store

GEN PodcastsBy Genetic Engineering and Biotechnology News

  • 4.6
  • 4.6
  • 4.6
  • 4.6
  • 4.6

4.6

5 ratings